Remibrutinib for severe itchy skin with unknown cause
Treatments studied
Part of Skin clinical trials.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have had itching for at least 4 months.
- Your itching is severe (scored 7 or more on a 0–10 scale) even with regular moisturizers.
- The itching is not caused by another known skin condition, illness, or medication.
- The itching affects at least two of these areas: trunk, arms, or legs.
- You are a candidate for systemic therapy (medication that works throughout the body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
This trial tests an investigational drug called ATTO-1310 to see if it can reduce chronic itching that has no clear cause. It may help people who have tried antihistamines without success.
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
Hear when a new Chronic Pruritus of Unknown Origin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.